Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

How to Store BPC-157: Protecting Your Research Investment

You’ve invested in high-purity research peptides. You’ve planned your experiments with precision. But there's a crucial, often overlooked step that can make or break the validity of your entire project: storage. Let’s be honest, this is critical. Improperly ha

You’ve invested in high-purity research peptides. You’ve planned your experiments with precision. But there's a crucial, often overlooked step that can make or break the validity of your entire project: storage. Let’s be honest, this is critical. Improperly handling a sensitive compound like BPC-157 isn't just a minor mistake; it's a catastrophic waste of time, resources, and potential data. It can lead to inconsistent results, failed experiments, and a formidable amount of frustration.

Our team at Real Peptides has seen it all. We meticulously craft our peptides through small-batch synthesis to guarantee purity and exact amino-acid sequencing, but that precision is meaningless if the compound degrades on a lab shelf. Understanding how to store BPC-157 isn't just 'best practice'—it's a non-negotiable element of rigorous scientific inquiry. We're here to walk you through the exact protocols we use and recommend, ensuring the integrity of your peptide from the moment it arrives to its final application.

The Unseen Enemy: Why Peptide Stability Is So Fragile

Before we dive into the 'how,' it's essential to understand the 'why.' What makes a peptide like BPC-157 so delicate? It comes down to its fundamental structure. Peptides are short chains of amino acids linked together by peptide bonds. Think of it like a very specific, intricately folded string of beads. This structure is what gives the peptide its biological activity. It's also what makes it vulnerable.

Several environmental factors act as relentless aggressors against these bonds:

Temperature: Heat provides energy that can cause the peptide chain to vibrate, unfold, and even break apart. This process, known as denaturation, is often irreversible. It’s the same reason an egg white turns solid when you cook it.

Oxidation: Oxygen in the air can react with certain amino acids in the chain, altering the peptide’s structure and rendering it inactive. This is a slow, creeping process that happens at room temperature.

Light: UV radiation from sunlight or even harsh indoor lighting carries enough energy to sever peptide bonds, effectively destroying the molecule.

Mechanical Stress: This one surprises many researchers. Vigorous shaking or agitation can physically shear the delicate peptide chains apart. It's a brute-force method of destruction.

When you receive a vial of BPC 157 Peptide, it’s in a lyophilized (freeze-dried) state. This process removes water, placing the peptide in a state of suspended animation where it's far more resilient to these degrading factors. But the moment you reconstitute it, the clock starts ticking. Fast. Your storage protocol from that point forward dictates its effective lifespan.

Storing Lyophilized (Freeze-Dried) BPC-157

This is stage one. Your peptide has arrived, sealed and in its powdered form. At this point, your goal is to maintain its suspended state for as long as possible. The rules are simple but absolute.

Temperature is Paramount.

We can't stress this enough: a freezer is the gold standard. Storing lyophilized BPC-157 at -20°C (-4°F) or colder will preserve its integrity for years. It dramatically slows down any potential degradation pathways. For researchers planning long-term studies or stocking up, this is the only way to go.

What if you don't have long-term freezer space? A standard refrigerator (around 2-8°C or 36-46°F) is acceptable for short-term storage, typically a few months. However, our experience shows a significant, sometimes dramatic, drop-off in stability over time compared to freezer storage. If your project timeline is longer than a couple of months, make room in the freezer. It’s worth it.

Keep It In The Dark.

Light degradation is a real threat. Never store your peptide vials on an open lab bench or shelf where they might be exposed to sunlight or even prolonged, direct artificial light. The box they arrive in is perfect for this. Our advice? Keep the vial in its original packaging, inside a dark fridge or freezer. Simple.

Moisture is the Enemy.

Lyophilization works because it removes water. Accidentally reintroducing it before you're ready is a recipe for disaster. Moisture, especially from condensation, can begin to degrade the peptide powder prematurely. Keep the vial tightly sealed until the exact moment you're ready for reconstitution. Don't open it just to 'take a look.'

The Art of Reconstitution: A Step-by-Step Protocol

This is where precision matters most. Reconstitution is the process of adding a liquid solvent to the freeze-dried powder to prepare it for use. Done correctly, it’s a seamless transition. Done incorrectly, it can destroy the peptide before you've even used it once.

First, you need the right tool for the job. For almost all research applications involving multi-use vials, we exclusively recommend using Bacteriostatic Water. It's sterile water that contains 0.9% benzyl alcohol, which acts as a preservative. This tiny addition prevents bacterial growth in the vial after it's been punctured by a needle, which is absolutely essential for maintaining purity over the life of the solution.

Here's the process our own lab teams follow:

Temperature Acclimation: Take the BPC-157 vial and the bacteriostatic water vial out of the refrigerator. Let them sit at room temperature for about 15-20 minutes. This prevents thermal shock to the peptide and reduces condensation.

Sterilize: Wipe the rubber stopper of both vials with an alcohol prep pad.

Draw the Water: Using a sterile syringe, draw up the precise amount of bacteriostatic water needed for your desired concentration.

The Gentle Introduction: Puncture the BPC-157 vial's rubber stopper with the needle. Here’s the key part: angle the needle so the stream of water runs down the inside wall of the vial. Do NOT squirt the water directly onto the peptide powder. This direct force can damage the molecules.

The Swirl, Not the Shake: Once the water is in, remove the syringe. Now, gently swirl the vial in a slow, circular motion. You can also roll it between your palms. The powder will dissolve. This might take a minute or two. Be patient. Whatever you do, DO NOT SHAKE THE VIAL. Shaking creates that mechanical stress we talked about, shearing the peptide chains and ruining your expensive compound.

That's it. You've now successfully reconstituted your BPC-157. The clock has officially started.

How to Store BPC-157 After Reconstitution

Once it's in liquid form, BPC-157 becomes significantly more fragile. The rules change, and there's no room for error.

The Refrigerator is Now Mandatory.

Your reconstituted BPC-157 must live in the refrigerator (again, 2-8°C or 36-46°F). No exceptions. Leaving it at room temperature for even a few hours will initiate rapid degradation. We've seen studies suggesting a significant loss of potency within 24 hours at room temp.

And a crucial point: never, ever freeze a reconstituted peptide. The formation of ice crystals creates sharp, microscopic edges that will physically shred the peptide structures. This is one of the most common and devastating mistakes we see. Lyophilized goes in the freezer; liquid goes in the fridge.

Light and Location Matter.

Just like with the powder, keep the liquid peptide protected from light. Store it in a dark box or wrap the vial in foil. Furthermore, avoid storing it in the refrigerator door. The temperature fluctuations from the door opening and closing can accelerate degradation. Find a stable, cold spot in the back of the main compartment.

Shelf Life.

Properly reconstituted with bacteriostatic water and stored in a dark, cold refrigerator, BPC-157 is generally stable for up to 30 days. Some research suggests it might last up to 6 weeks, but to ensure maximum potency for your experiments, we recommend planning for a 30-day window. If you use sterile water (which lacks the preservative), the solution should be used within 24-48 hours to avoid bacterial contamination.

Ideal Temperature

Freezer (-20°C / -4°F)

Refrigerator (2°C – 8°C / 36°F – 46°F)

Acceptable Short-Term

Refrigerator (2°C – 8°C) for a few months

N/A – Must be refrigerated

Light Exposure

Must be stored in the dark

Handling

Keep vial sealed until use

Gentle swirling to mix; NEVER shake

Solvent

N/A

Bacteriostatic Water (recommended)

Estimated Shelf Life

Years in freezer; months in refrigerator

Approx. 30 days with bacteriostatic water

The Alternative: What About BPC-157 Capsules?

It's worth noting that not all BPC-157 requires this level of meticulous cold-chain management. For certain research models, particularly those exploring oral administration pathways, stabilized capsules offer a completely different protocol. Our BPC 157 Capsules, for example, are formulated for ambient temperature stability.

They contain the peptide along with specialized excipients and are sealed in a way that protects them from light, moisture, and air. The storage instructions are much simpler: keep them in a cool, dry place like a cupboard or drawer, away from direct sunlight and extreme heat. No refrigeration or reconstitution is required. This highlights how the form of the peptide dictates its handling—a critical distinction for any researcher to understand.

Traveling with Your Research Peptides

What happens when your research moves out of the lab? Transporting BPC-157 requires planning. It's a difficult, often moving-target objective.

For lyophilized vials, the main goal is to keep them from getting hot. If you're traveling for a short period, keeping them in a bag away from sunlight is often sufficient. For longer trips, especially in warm climates, placing them in an insulated bag is a smart move.

For reconstituted BPC-157, it's a different story. You must maintain the cold chain. A small insulated lunch bag with a cold pack is essential. Make sure the vial is padded to prevent it from breaking and is not in direct contact with a frozen ice pack (to avoid accidental freezing). Wrap it in a paper towel first. This approach, which we've refined over years of shipping temperature-sensitive compounds, ensures stability during transit.

The Foundation of Stability: Purity

We've spent all this time discussing how to preserve your peptide. But there's an unspoken prerequisite: you must start with a pure, stable, correctly synthesized peptide. All the perfect storage techniques in the world can't save a poorly made product.

This is the core of our philosophy at Real Peptides. Contaminants, incorrect amino acid sequences, or leftover synthesis reagents from a subpar manufacturing process can act as catalysts, accelerating the degradation of the peptide itself. A 99%+ pure peptide is inherently more stable than one that's only 95% pure because there are fewer reactive impurities in the vial.

Our commitment to small-batch synthesis and rigorous quality control isn't just about providing accurate compounds—it’s about providing reliable compounds. This principle of purity-driven stability applies across our entire catalog, from foundational peptides like BPC-157 and TB-500 to more complex molecules like Tesamorelin. When you start with an impeccably pure product, your storage protocol is protecting a compound that is actually worth protecting.

Properly storing BPC-157 isn't just a task on a checklist. It's an active and ongoing part of the scientific method. It's about controlling variables, respecting the delicate nature of the tools you work with, and ultimately, ensuring that the results you generate are both accurate and reproducible. By following these protocols, you're not just protecting a peptide; you're safeguarding the integrity of your research. When you're ready to build your next project on a foundation of uncompromising quality, from synthesis to storage, you can browse our full collection of research peptides and see the difference for yourself.

Frequently Asked Questions

We strongly advise against this. The plastic and rubber in syringes are not designed for long-term storage of peptides, and there’s a much higher risk of contamination and loss of stability. It’s always best to draw up each dose immediately before use from the refrigerated vial.

If left at room temperature for an extended period (8+ hours), the peptide will have begun to degrade significantly. While it may not be completely inert, its potency will be compromised, leading to unreliable results. For the sake of data integrity, we would recommend discarding the vial and starting fresh.

Unfortunately, there are no obvious visual cues like color change for peptide degradation. The liquid should remain clear. If it becomes cloudy or has visible particulates, it’s a sign of bacterial contamination or precipitation, and it must be discarded immediately. Potency loss is invisible.

Bacteriostatic water contains 0.9% benzyl alcohol, which acts as a preservative. This prevents the growth of bacteria inside the vial after the rubber stopper has been punctured multiple times. It’s essential for maintaining sterility and safety in any multi-use vial.

No, we don’t recommend this. The temperature in the door of a refrigerator fluctuates significantly every time it’s opened. Peptides require a stable, cold environment, which is best found at the back of a main shelf.

Yes, absolutely. Peptides are complex, folded chains of amino acids. The mechanical shear force from shaking can physically break these chains apart, a process called denaturation. This permanently destroys the peptide’s structure and renders it biologically inactive.

While some researchers do this, we don’t officially recommend it unless you’re certain of their chemical compatibility and stability when mixed. Mixing different peptides can potentially alter their pH and structure, leading to degradation or reduced efficacy. For the purest data, use separate injections.

A cloudy solution is a major red flag. It typically indicates either bacterial contamination or that the peptide has crashed out of solution (precipitated). In either case, the product should not be used and must be discarded safely.

While a freezer (-20°C) is ideal for long-term storage (years), lyophilized BPC-157 can be stored in a standard refrigerator (2-8°C) for several months without significant degradation. If your research is expected to last longer than 3-4 months, we highly recommend using a freezer.

Tap water and bottled water are non-sterile and contain minerals, impurities, and often chlorine. These can instantly contaminate and degrade the peptide, rendering it useless and unsafe for research. Only use sterile bacteriostatic water or, for immediate single-use, sterile water.

No, our stabilized [BPC 157 Capsules](https://www.realpeptides.co/products/bpc-157-capsules/) are designed for ambient storage. They should be kept in a cool, dry place away from direct sunlight, such as a pantry or cabinet. Their formulation protects them from degradation without needing refrigeration.

The two most catastrophic mistakes are shaking the vial after reconstitution and freezing the liquid peptide. Both actions cause irreversible physical damage to the peptide chains, completely destroying the product’s integrity. Gentle handling and proper temperatures are non-negotiable.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 Gastric Protection Complete Guide 2026: Research Timeline and Dosing

Preclinical rodent models (1993–2024) 10 mcg/kg to 1 mg/kg Intraperitoneal, oral, intragastric Ulcer surface area reduction Consistent 50–70% reduction in ulcer area vs controls at 10 mcg/kg within 7–14 days Most robust evidence base exists here—mechanism is reproducible across injury models Human case series (Eastern Europe, 2000–2015) 200–400 mcg/day Oral capsule Symptom resolution in IBD patients Anecdotal improvement in 60–80% of cases; no placebo control Promising but methodologically weak—publication bias likely Regulatory status (2026) N/A FDA approval for human use Zero approved indications—remains research-only compound Legal access limited to academic/commercial research contexts The preclinical timeline spans three decades. Early work by Croatian researcher Sikiric et al. (1993) established the protective effect against ethanol-induced gastric lesions. Subsequent studies expanded to NSAID ulcers, stress ulcers, ischemia-reperfusion injury, and inflammatory bowel disease models. The 10 mcg/kg dose became the reference standard because it consistently produced maximal effect without adverse events—higher doses (up to 1 mg/kg) showed no additional benefit, indicating a plateau in the dose-response curve. Human data remains sparse. Case series from Eastern European clinics (not peer-reviewed randomized trials) reported symptom improvement in patients with Crohn's disease, ulcerative colitis, and refractory gastric ulcers when given 200–400 mcg/day orally. These report…
STORAGE

Peptide Structure and Stability

The molecular structure of BPC-157 comprises 15 amino acids arranged in a specific sequence that confers exceptional stability under physiological conditions. This pentadecapeptide demonstrates resistance to degradation in gastric juice, a property that distinguishes it from many therapeutic peptides that require modified administration routes to avoid gastric inactivation. The peptide's stability profile allows for both oral and parenteral administration, with documented biological activity through multiple delivery routes including subcutaneous, intramuscular, intraperitoneal, and oral administration. Pharmacokinetic studies in rats and beagle dogs reveal that BPC-157 exhibits linear pharmacokinetic characteristics across all tested doses. Following single administration, the elimination half-life of prototype BPC-157 was less than 30 minutes in both species, indicating rapid systemic clearance. The mean absolute bioavailability following intramuscular injection was approximately 14-19% in rats and 45-51% in beagle dogs, suggesting species-specific absorption characteristics relevant for dose translation to human applications. The metabolic pathway of BPC-157 involves rapid breakdown into various small peptide fragments in vivo, ultimately forming single amino acids that enter normal amino acid metabolism and excretion pathways. Radiolabeled [3H]BPC-157 studies demonstrate that the peptide is finally metabolized into single amino acids, represented primarily by proline, in…
02

Question drills

Open a question for its connected answer.

01What If I'm Not Seeing Results After Four Weeks at 500mcg Daily?+

Review your reconstitution and storage protocol first. Most 'non-responder' cases trace to degraded peptide, not biological resistance. If storage was correct, assess mechanical load: are you resting the injury enough for angiogenesis and collagen remodeling to occur, or are you continuing high-impact activity that re-injures tissue faster than BPC-157 can facilitate repair? The peptide accelerates healing; it doesn't override continued damage. Finally, verify your source's third-party testing. A vial marketed at 98% purity that actually contains 65% BPC-157 will underperform regardless of dosing discipline.

SOURCE / realpeptides.co ↗
02What If I Have Active IBD — Will BPC-157 Work During a Flare?+

BPC-157 showed efficacy in rat models of active colitis, not just post-injury repair. Administer subcutaneously at 10–20 μg/kg during the active inflammatory phase. The peptide reduces TNF-α and IL-6 levels within 24 hours, which stabilises existing tight junctions before upregulating new protein synthesis. The dual action (anti-inflammatory + structural repair) is what makes it viable during flares. One caveat: severe ulceration may delay epithelial regeneration beyond the 72-hour tight junction repair window. Concurrent use of mucosal protectants (zinc carnosine, sucralfate) addresses that gap.

SOURCE / realpeptides.co ↗
03What If I Accidentally Shook the Vial Instead of Swirling It?+

Refrigerate immediately and wait 30 minutes. Mechanical agitation from shaking creates foam and introduces air-liquid interfaces where peptides denature, but if the exposure was brief (10–15 seconds of shaking), much of the cloudiness may still be reversible aggregation rather than permanent denaturation. The foam itself will dissipate within 5–10 minutes, and if underlying cloudiness clears with refrigeration, the peptide remains usable. If cloudiness persists or you shook the vial vigorously for more than 30 seconds, the shear forces likely caused irreversible surface denaturation. Discard and reconstitute a fresh vial using proper technique.

SOURCE / realpeptides.co ↗
04What If BPC-157 Studied ACL Injury Recovery Doesn't Translate to Humans?+

This is the most likely scenario based on the current evidence gap. Rodent ligament healing occurs on a 14–28 day timeline; human ACL reconstruction rehab spans 6–9 months. The inflammatory response, biomechanical loading patterns, and vascular density in human knees differ substantially from animal models. Even if the cellular mechanisms are conserved across species, the magnitude of effect may be negligible in humans. Athletes who invest in BPC-157 without clinical trial data are accepting this uncertainty. There is no fallback or refund if it provides zero benefit.

SOURCE / realpeptides.co ↗
05What If Pain Increases During the First Week of BPC-157 Administration?+

Increased pain during days 2–5 can indicate heightened inflammatory signaling as repair processes accelerate. Not tissue damage. BPC-157 upregulates growth factors that recruit immune cells to the injury site, which temporarily increases local inflammation before resolution begins. If pain persists beyond 7 days or worsens progressively, reassess injury severity with imaging. The peptide accelerates healing but doesn't reverse structural failures like complete tendon ruptures that require surgical intervention.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

BPC-157 Studied Diabetic Neuropathy Research — Real Peptides

Fewer than 15% of compounds showing neuroprotective effects in diabetic rat models ever demonstrate meaningful clinical translation. BPC-157 studied diabetic neuropathy research has now appeared in peer-reviewed journals from research groups in Croatia, China, and Japan. Each showing similar patterns of peripheral nerve regeneration, reduced inflammatory markers, and improved motor function recovery. The peptide's mechanism involves VEGF (vascular endothelial growth factor) upregulation and modulation of inflammatory cytokines like TNF-alpha and IL-6, both central to diabetic neuropathy progression. Our team has reviewed this body of research alongside the broader peptide literature for years. The gap between what most suppliers claim about regenerative peptides and what the actual research demonstrates is massive. But BPC-157 studied diabetic neuropathy research is one of the few areas where the preclinical evidence base is unusually robust. What does BPC-157 studied diabetic neuropathy research show about nerve regeneration potential? BPC-157 studied diabetic neuropathy research demonstrates statistically significant improvements in nerve conduction velocity, reduced mechanical allodynia (pain response to non-painful stimuli), and histological evidence of myelin sheath repair in diabetic rat models. The peptide acts through VEGF pathway activation and anti-inflammatory cytokine modulation. Mechanisms directly relevant to the microvascular damage and chronic inflammation that drive diabetic neuropathy. Studies published between 2018–2024 show dose-dependent effects at 10–100 mcg/kg administered intraperitoneally or subcutaneously. This isn't another peptide being repurposed from unrelated research. BPC-157 studied diabetic neuropathy research emerged because the compound's known angiogenic properties. Stimulating new blood vessel formation. Made it a logical candidate for peripheral nerve conditions driven by microvascular insufficiency. Diabetic neuropathy damages the tiny blood vessels (vasa nervorum) that supply peripheral nerves, causing axonal degeneration and demyelination. If a peptide can restore microvascular blood flow while simultaneously reducing inflammatory damage, it addresses both upstream causes of nerve injury. This piece covers the specific mechanisms documented in published research, what the animal models actually show versus what they don't, and why BPC-157 studied diabetic neuropathy research remains preclinical despite promising early data.

RESEARCH

Research perspective on BPC-157: potential therapeutic applications

BPC-157 is a “Pentadeca Peptide” which was derived from a naturally occurring peptide found in gastric secretions. In other words, a healthy stomach produces, in very small amounts, this unique peptide, which helps keep the lining of the stomach intact. Researchers figured out a way to make a stable version of this peptide, and BPC-157 was born. There are few peptides out there that have such a far-reaching effect on so many aspects of health. Most peptides are releasers of Growth Hormone, and have very little effect outside of the reach of benefits found from increased GH release. What makes BPC-157 so special to me, is that it positively affects every aspect of health. It can heal stomach ulcers, it can repair nerves, and soft tissue (aka ligaments and tendons). It also has been shown to reduce depressive behaviours as well as protect against addiction mechanisms (via its effect on GABA transmission as well as Dopamine and serotononin transmission, etc.) Here’s a quick break-down of the top 5 benefits of BPC-157. Say Good-bye to Ulcers BPC-157 was originally developed because it was found in gastric acid, and promotes healing of gastric ulcers, as well as intestinal health. What’s more, this is one of the few peptides that has an effect when taken orally. Something that other peptides can’t promise.“particularly, it has a prominent effect on alcohol-lesions (i.e. acute, chronic) and naiads lesions (interestingly, bpc 157 both prevents and reverses adjuvant arthritis). In rat esophagitis and failed function of both lower esophageal sphincter (les) and pyloric sphincters (ps), bpc 157 increased pressure in both sphincters till normal and reduced esophagitis.” Anti-Inflammatory Effects BPC-157 has far-reaching anti-inflammatory benefits, and has been studied for its effect on gingivitis and periodontitis (inflammation of the gums and oral-tissue). “The pentadecapeptide bpc 157 has been shown to have anti-inflammatory and wound healing effects on multiple target tissues and organs. The purpose of the present study was to investigate the effect of bpc 157 on inflammation and bone resorption in experimental periodontitis in rats. First the acute effect of bpc was tested on gingival blood flow by laser doppler flowmetry. Then periodontitis was produced by a silk ligature placed around the lower left first molar. Rats were treated with bpc 157 (once daily for 12 days) or vehicle. At day 13, the gingivomucosal tissues encircling the molars were removed on both sides. Inflammation was assessed by evans blue plasma extravasation technique and by histology. Alveolar bone loss was analyzed by microct. Bpc 157 had no effect on gingivomucosal blood flow. Twelve day ligature caused a significantly increased evans blue extravasation in the gingivomucosal tissue, histological signs of inflammation, and alveolar bone destruction. Bpc 157 treatment significantly reduced both plasma extravasation, histological alterations and alveolar bone resorption. In conclusion, systemic application of bpc 157 does not alter blood circulation in healthy gingiva. Chronic application of the peptide has potent antiinflammatory effects on periodontal tissues in ligature induced periodontitis in rats. Taken together, this proof of concept study suggests that bpc 157 may represent a new peptide candidate in the treatment of periodontal disease.” Soft-Tissue Healing One of the most important effects of BPC-157, even though I don’t focus on it as much, is that it positively impacts the healing of soft tissue. Ligament and tendon healing is very difficult to pull off. There is very little blood-flow to this tissue in the body. Most peptides that affect GH levels have very little effect on soft tissue, and this makes BPC-157 unique in its own right. “We improved medial collateral ligament (mcl) healing throughout 90 days after surgical transection. We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier. Previously, as an effective peptide therapy, stable gastric pentadecapeptide bpc 157 (gepppgkpaddaglv, an anti-ulcer peptide effective in inflammatory bowel disease therapy (pl 14736)) particularly improved healing of transected tendon and muscle and wound healing effect including the expression of the early growth response 1 (egr-1) gene. After mcl transaction bpc 157 was effective in rats when given once daily intraperitoneally (10 microg or 10 ng/kg) or locally as a thin layer (1.0 microg dissolved in distilled water/g commercial neutral cream) at the site of injury, first application 30 min after surgery and the final application 24 h before sacrifice. Likewise, bpc 157 was effective given per-orally (0.16 microg/ml in the drinking water (12 ml/day/rat)) until sacrifice. Commonly, bpc 157 microg-ng-rats exhibited consistent functional, biomechanical, macroscopic and histological healing improvements. Thus, we suggest bpc 157 improved healing of acute ligament injuries in further ligament therapy.” Antidepressant Effects BPC-157 is one of the only peptides I’ve ever researched that has a dramatic effect on mood and wellbeing. Sure, the benefits of increased GH output from peptides like Ipamorelin can have an effect on mood and wellbeing. But when it comes to a specific effect on mood and mental health, BPC-157 stands alone. “Various antidepressants have antiulcer activity. Likewise, the models currently used in ulcers and depression disorders research have a considerable degree of similarity. Therefore, the possibility that depression disorders could be effectively influenced by a primary antiulcer agent with a cyto/organoprotective activity, such as the novel stomach pentadecapeptide bpc 157, was investigated in two rat depression assays. First, a forced swimming test (a porsolt’s procedure) was used. As a more severe procedure, chronic unpredictable stress (after 5 d of unpredictable stress protocol, once daily drug application during stress procedure, open field-immobility test assessment at fourth or sixth day of medication) was used. In a forced swimming test, a reduction of the immobility time in bpc 157 (10 microg, 10 ng x kg(-1) i.p.) treated rats corresponds to the activity of the 15 mg or 40 mg (i.p.) of conventional antidepressants, imipramine or nialamide, respectively, given according to the original porsolt’s protocol. In chronic unpredictable stress procedure, particular aggravation of experimental conditions markedly affected the conventional antidepressant activity, whereas bpc 157 effectiveness was continuously present. The effect of daily imipramine (30 mg) medication could be seen only after a more prolonged period, but not after a shorter period (i.e., 4-d protocol). In these conditions, no delay in the effectiveness was noted in bpc 157 medication and a reduction of the immobility of chronically stressed rats was noted after both 4 and 6 d of bpc 157 (10 microg, 10 ng) medication.” Addiction-Fighting Effects Last, but not least, BPC-157 has a strong effect on addiction-related neurotransmission. It enhances GABA transmission and reduces benzodiazepine tolerance. “A novel gastric pentadecapeptide bpc 157 with different beneficial activities and anticonvulsant effect interacting with gabaergic system could improve diazepam efficacy coadministered (10 microg/kg, 10 ng/kg i.p.) with diazepam (5.0 mg/kg i.p.) twice daily for 10 days, since diazepam chronic medication would otherwise predispose for diazepam- tolerance/withdrawal development (shorter latency to convulsion after convulsant). In diazepam chronically treated mice, it attenuated diazepam tolerance (provoked by later acute administration of diazepam together with convulsant) and postponed physical dependence/withdrawal effects (provoked by later administration of isoniazid). In tolerance assay, at 42 h after the end of conditioning regimen, shorter preconvulsive latencies than in healthy (non-diazepam conditioned) mice following isoniazid (800 mg/kg i.p.) (as hallmark of tolerance) were observed if diazepam (5.0 mg/kg i.p.) was again given acutely to mice previously conditioned with diazepam alone (use of picrotoxin 3.0 mg/kg i.p., as convulsant, with acute application of diazepam in previously diazepam conditioned mice did not lead to tolerance hallmark). This was completely avoided in diazepam+bpc 157 10 microg or diazepam+bpc 157 10 ng chronically treated animals. In physical dependence assay (isoniazid challenge assessed at 6, 14, 42 and 72 h after conditioning medication), when compared to diazepam non-conditioned healthy mice, in diazepam conditioned mice residual anticonvulsive activity was not present already at the earliest post-conditioning interval (i.e., not different latency to isoniazid-convulsions), whereas shorter preconvulsive latencies (as physical dependence/withdrawal hallmark) were noted in diazepam conditioned mice following isoniazid challenge at 42 h and at 72 h after end of conditioning treatment. In diazepam+bpc 157 10 microg- conditioned mice, a residual anticonvulsive activity (i.e., longer latency to isoniazid convulsion) was noted at 6 h post-conditioning, whereas shorter preconvulsive latencies appeared only at 72 h-post-conditioning period. In conclusion, taken together these data (lack of tolerance development (tolerance studies), prolonged residual anticonvulsive activity, and postponed physical dependence/withdrawal hallmark in diazepam+bpc 157 chronically treated mice) with common benzodiazepines tolerance/withdrawal knowledge, it could be speculated that bpc 157 acts favoring the natural homeostasis of the gaba receptor complex as well as enhancing the gabaergic transmission, and having a mechanism at least partly different from those involved in diazepam tolerance/withdrawal, it may be likely used in further therapy of diazepam tolerance and withdrawal.” And also reduces the hyperactivity that occurs when methamphetamine was administered to rats. “Stabile gastric pentadecapeptide bpc 157, gly–glu–pro–pro–pro–gly–lys–pro–ala–asp–asp–ala–gly–leu–val, mw 1419, has a variety of protective effects in different organs, as well as nervous system. It antagonizes haloperidol-induced behavioural supersensitivity to amphetamine which, results in dopaminergic neurotoxicity and nigrostriatum damage due to increased lipid peroxidation. Currently, bpc 157 neuroprotective effects are evaluted in a model of haloperidol- and methamphetamine-induced neurotoxicity. These models result in impaired motoric function and increased lipid peroxidation in different brain regions. The purpose of this research was to asses bpc 157 protective effects on nigrostriatum in rat model of haloperidol and methamphetamine induced neurotoxicity using fine motoric in rats as indicator of nigrostriatum function and malondialdehyde (mda) levels as lipid peroxidation marker.” WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., Sever, M., & Slobodnjak, Z. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 16(10), 1224–1232. PubMed Staresinic, M., Petek, M., Perovic, D., Coric, V., Zoricic, I., Zoricic, Z., & Sikiric, P. (2003). Healing of Achilles tendon in rats: advanced healing by BPC 157 and its possible mechanisms. Journal of Orthopaedic Research, 21(5), 976–983. PubMed Vukojevic, J., Sikiric, P., et al. (2018). Pentadecapeptide BPC 157 and the healing of transected quadriceps muscle in rats: new insights. European Journal of Pharmacology, 833, 160–170. PubMed Seiwerth, S., Brcic, L., Vuletic, L. B., Kolenc, D., & Sikiric, P. (2014). BPC 157 and blood vessels. Current Pharmaceutical Design, 20(7), 1121–1125. PubMed Mihovilovic, K., Sever, M., Zoricic, I., et al. (2007). Anti-inflammatory and anti-ulcer effects of stable gastric pentadecapeptide BPC 157 in rodent models of gastrointestinal lesions and periodontitis. Journal of Physiology and Pharmacology, 58(Suppl 5), 161–176. PubMed Sikiric, P., Hahm, K. B., Blagaic, A. B., & Tvrdeic, A. (2020). Stable gastric pentadecapeptide BPC 157, safe in clinical trials, may solve major health problems. World Journal of Gastroenterology, 26(24), 3090–3107. PubMed

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Micro-Dosing vs Standard Protocols

Understanding the differences between micro-dosing and standard protocols helps determine which approach suits specific situations. Neither approach is universally superior. The o…

Comparison

BPC-157 Studied Stress Fracture: Comparison Across Bone Healing Interventions

BPC-157 (animal models) VEGF upregulation, eNOS activation, MSC recruitment to fracture site 40–60% faster radiographic union in rodent studies Controlled animal trials; no Phase …